Benign Prostatic Hyperplasia and Prostatitis Device-based Treatments Market

Symptomatic benign prostatic hyperplasia (BPH) and prostatitis affect more than 100 million men worldwide, lowering quality of life with painful symptoms that can be difficult to manage. The global market for devices to treat symptomatic BPH and prostatitis includes minimally invasive surgical and therapy systems, as well as implants aimed at alleviating or treating severe symptoms. Markets covered by this global analysis include the United States, the five major European markets (France, Germany, Italy, Spain, and the United Kingdom), Japan, and the rest of the world. 

The global market for devices used in the treatment of symptomatic BPH was valued at $421.0m in 2016 and is forecast to increase at a compound annual growth rate of 6.8%, reaching an estimated $586.1m by 2021.